Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ALBTNASDAQ:BCTXNASDAQ:EGRXNASDAQ:UBX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeALBTAvalon GloboCare$3.46+0.9%$3.49$2.11▼$12.60$6.50M0.03478,632 shs1.19 million shsBCTXBriacell Therap$3.11+6.1%$3.58$2.78▼$29.40$19.85M1.3567,989 shs237,580 shsEGRXEagle Pharmaceuticals$2.70-1.8%$2.07$1.50▼$2.88$35.07M0.838,865 shs1,123 shsUBXUNITY Biotechnology$0.79-0.4%$0.84$0.66▼$3.10$13.57M1.05164,559 shs61,728 shs13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceALBTAvalon GloboCare+0.87%+16.69%-7.61%-34.35%-51.44%BCTXBriacell Therap+6.14%-0.32%-0.32%-21.66%-81.24%EGRXEagle Pharmaceuticals0.00%+14.89%+38.46%+206.82%-45.12%UBXUNITY Biotechnology-0.43%-0.66%+6.38%-31.14%-43.12%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationALBTAvalon GloboCare2.435 of 5 stars0.05.00.04.33.41.70.0BCTXBriacell Therap2.1493 of 5 stars3.52.00.00.03.30.00.6EGRXEagle Pharmaceuticals2.6606 of 5 stars0.04.00.03.90.03.30.0UBXUNITY Biotechnology3.8185 of 5 stars3.32.00.04.72.20.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceALBTAvalon GloboCare 0.00N/AN/AN/ABCTXBriacell Therap 3.00Buy$32.00928.94% UpsideEGRXEagle Pharmaceuticals 0.00N/AN/AN/AUBXUNITY Biotechnology 2.50Moderate Buy$3.75377.71% UpsideCurrent Analyst Ratings BreakdownLatest ALBT, UBX, EGRX, and BCTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/27/2025UBXUNITY BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$4.00 ➝ $2.005/16/2025UBXUNITY BiotechnologyMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Neutral$6.00 ➝ $1.004/23/2025UBXUNITY BiotechnologyChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/23/2025UBXUNITY BiotechnologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.00 ➝ $4.004/22/2025BCTXBriacell TherapHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$32.00 ➝ $32.00(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookALBTAvalon GloboCare$1.33M4.92N/AN/A($11.37) per share-0.30BCTXBriacell TherapN/AN/AN/AN/A$1.76 per shareN/AEGRXEagle Pharmaceuticals$257.55M0.14$6.75 per share0.40N/A∞UBXUNITY Biotechnology$240K56.29N/AN/A$0.39 per share2.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateALBTAvalon GloboCare-$7.90M-$19.96N/A∞N/A-647.29%N/A-50.13%8/18/2025 (Estimated)BCTXBriacell Therap-$4.79M-$8.32N/AN/AN/AN/A-479.97%-182.26%N/AEGRXEagle Pharmaceuticals$35.64MN/A0.00∞N/AN/AN/AN/AN/AUBXUNITY Biotechnology-$25.99M-$1.62N/AN/AN/AN/A-246.82%-58.81%7/22/2025 (Estimated)Latest ALBT, UBX, EGRX, and BCTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/13/2025Q3 2025BCTXBriacell Therap-$1.76-$1.64+$0.12-$1.64N/AN/A5/13/2025Q1 2025ALBTAvalon GloboCareN/A-$1.43N/A-$1.43N/AN/A4/22/2025Q1 2025UBXUNITY Biotechnology-$0.43-$0.43N/A-$0.43N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthALBTAvalon GloboCareN/AN/AN/AN/AN/ABCTXBriacell TherapN/AN/AN/AN/AN/AEGRXEagle PharmaceuticalsN/AN/AN/AN/AN/AUBXUNITY BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioALBTAvalon GloboCareN/A0.190.19BCTXBriacell TherapN/A3.413.41EGRXEagle PharmaceuticalsN/AN/AN/AUBXUNITY BiotechnologyN/A1.951.95Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipALBTAvalon GloboCare1.42%BCTXBriacell Therap15.42%EGRXEagle Pharmaceuticals85.36%UBXUNITY Biotechnology29.49%Insider OwnershipCompanyInsider OwnershipALBTAvalon GloboCare37.30%BCTXBriacell Therap5.73%EGRXEagle Pharmaceuticals28.90%UBXUNITY Biotechnology5.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableALBTAvalon GloboCare51.89 million1.19 millionNot OptionableBCTXBriacell Therap86.78 million6.39 millionOptionableEGRXEagle Pharmaceuticals10012.99 million9.23 millionNo DataUBXUNITY Biotechnology6017.21 million16.21 millionOptionableALBT, UBX, EGRX, and BCTX HeadlinesRecent News About These CompaniesUnity Biotechnology Inc News (UBX) - Investing.comJune 26 at 1:10 PM | investing.comUBX Unity Biotechnology, Inc. - Seeking AlphaJune 24 at 8:09 PM | seekingalpha.comHC Wainwright & Co. Downgrades Unity Biotechnology (UBX)May 28, 2025 | msn.comUnity Biotechnology (UBX) was downgraded to a Hold Rating at Mizuho SecuritiesMay 18, 2025 | theglobeandmail.comBay Area biotech company Unity lays off every single worker, including CEOMay 6, 2025 | msn.comBay Area biotech company Unity, once worth $700M, lays off entire remaining workforceMay 5, 2025 | msn.comSouth San Francisco biotech company lays off entire workforce, including CEOMay 5, 2025 | msn.comUnity disbands workforce as it searches for strategic path forward, while Mammoth cuts 24 rolesMay 5, 2025 | fiercebiotech.comFUNITY Biotechnology to Present at the ARVO 2025 Annual MeetingMay 1, 2025 | globenewswire.comNEJM Evidence publishes results from Phase 2 BEHOLD study of UBX1325April 25, 2025 | ophthalmologytimes.comOUNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business UpdatesApril 22, 2025 | globenewswire.comUnity Biotechnology price target lowered to $4 from $8 at H.C. WainwrightMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology price target lowered to $4 from $6 at ChardanMarch 26, 2025 | markets.businessinsider.comUnity Biotechnology announces results from ASPIRE Phase 2b study in DMEMarch 25, 2025 | markets.businessinsider.comUnity reports topline outcomes from trial of diabetic macular oedema therapyMarch 25, 2025 | msn.comUNITY Biotechnology tanks on mixed results for eye disease drugMarch 25, 2025 | thepharmaletter.comTUBX Stock Down 29% on Mixed Results From Phase II Eye Disease StudyMarch 25, 2025 | zacks.comUNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular EdemaMarch 24, 2025 | finance.yahoo.comUnity Biotechnology releases topline results from phase 2b ASPIRE trial of UBX1325 in patients with diabetic macular edemaMarch 24, 2025 | ophthalmologytimes.comOUNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trialMarch 24, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALBT, UBX, EGRX, and BCTX Company DescriptionsAvalon GloboCare NASDAQ:ALBT$3.46 +0.03 (+0.87%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$3.40 -0.06 (-1.73%) As of 04:31 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avalon GloboCare Corp., together with its subsidiaries, owns and operates commercial real estate properties in the United States and China. The company develops and delivers transformative cellular therapeutics, precision diagnostics, and clinical laboratory services. Its leading candidates are AVA-001, an anti-CD19 CAR-T, which has completed first-in-human clinical trial for relapsed/refractory (R/R) B-cell lymphoblastic leukemia; and AVA-011 that has completed pre-clinical laboratory studies and undergoing IND-enabling process development stage to generate cGMP-grade AVA-011 CAR-T cells. It is also developing mRNA-based Flash-CAR cell therapy platform. In addition, the company develops Avalon clinical-grade tissue-specific exosome (ACTEX); AVA-Trap, a therapeutic program provides an effective therapeutic option to combat COVID-19 and other life-threatening conditions involving cytokine storms; offers therapeutic and diagnostic targets utilizing QTY-code protein design technology with Massachusetts Institute of Technology (MIT), including using the QTY code protein design technology for development of a hemofiltration device to treat Cytokine Storm; and provides co-development of next generation, transposon-based, multi-target CAR-T, CAR-NK, and other immune effector cell therapeutic modalities with Arbele Limited. Avalon GloboCare Corp. has strategic partnership with HydroPeptide, LLC to engage in co-development and commercialization of a series of clinical-grade, exosome-based cosmeceutical, and orthopedic products; and corporate research agreement with the University of Pittsburgh of the Commonwealth System of Higher Education. The company was founded in 2016 and is headquartered in Freehold, New Jersey.Briacell Therap NASDAQ:BCTX$3.11 +0.18 (+6.14%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$2.98 -0.13 (-4.18%) As of 04:04 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.Eagle Pharmaceuticals NASDAQ:EGRX$2.70 -0.05 (-1.82%) As of 06/25/2025 10:56 AM EasternEagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.UNITY Biotechnology NASDAQ:UBX$0.78 0.00 (-0.43%) Closing price 06/26/2025 04:00 PM EasternExtended Trading$0.80 +0.01 (+1.78%) As of 04:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase 2 clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2048, a Tie2/VEGF bispecific; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Super Micro’s Bold $2B Bond Plan Signals 35% Premium Upside Is IBM’s AI Transformation Powering a Sustained Rally? Analysts Supercharge AMD Stock Ahead of Q2 AI Catalyst Amazon: Why Some Are Growing Bearish, and Why They’re Wrong ASML Keeps Buying Back Its Own Stock—Chasing Discount and Upside Astera Labs: AI Infrastructure Play With Significant Growth Ahead Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
